Genmab — Februar 2017
-

-
Hvilke spørgsmål Mcjean?
-
http://medwatch.dk/Medicinal___Biotek/article9347784.ece Lidt konkurrence.?
-
Nok snarere samarbejde. Der kører allerede kombi-studier med durvalumab i MM https://www.clinicaltrials.gov/ct2/results?term=fusion-mm-003&Search=Search og med Opdivo https://www.clinicaltrials.gov/ct2/results?term=daratumumab+opdivo&Search=Search i flere cancerformer.
-
har købt lidt Genmab Bull*3 de seneste dage. Kunne ikke lade være. Tror kursen vil fortsætte opad i takt med at udruldningen af darzalex brager derudad.
-
GILD med presset indtjening og $32 bn on hand http://finance.yahoo.com/news/gilead-sciences-announces-fourth-quarter-210100614.html
-
God morgen.

-
-
København, Danmark; 8. februar 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) har i dag meddelt, at Judith Klimovsky, MD, ansættes som Executive Vice President og Chief Development Officer (CDO). Dr. Klimovsky vil blive ansvarlig for selskabets globale aktiviteter inden for produktudvikling og indtræder i direktionen, som i øjeblikket består af selskabets Chief Executive Officer, Dr. Jan van de Winkel, og Chief Financial Officer, David Eatwell
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind